ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeutic candidates for cancer treatment.
ValiRx is a life sciences company focused on early-stage cancer therapeutics and women’s health.
The agreement will specifically focus on a series of dual-kinase inhibitor candidates, which ‘show promise’ in reversing resistance to current standard of care therapeutics in ovarian and other types of cancer. A similar approach has already been validated in clinical studies with other assets.
The evaluation process is expected to take a year. If milestones are met, the project will be considered for in-licensing on pre-agreed terms.
‘I’m delighted to announce the start of our second new evaluation project for 2024 with the signature of this agreement with Imperial College London. The scientific developments in this project display a high degree of quality and innovation with potential application in an exciting area of research,’ said Chief Executive Officer Suzy Dilly.
ValiRx shares were trading 0.9% higher at 3.79 pence each in London on Thursday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
